AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Evogene Plunges 11.02% on ICL Acquisition, Q4 Earnings
Generated by AI AgentAinvest Movers Radar
Tuesday, Apr 22, 2025 5:33 am ET1min read
On April 22, 2025, Evogene's stock price dropped by 11.02% in pre-market trading.
Evogene, a computational biology company, focuses on revolutionizing product development for life-science based industries, including human health,
, and industrial applications. The company's Computational Predictive Biology (CPB) platform is designed to computationally discover and develop life-science products based on microbes, small molecules, and genetic elements.Recently,
announced its acquisition of the activities of Evogene's subsidiary, Lavie Bio. Lavie Bio is known for its improvements in agriculture, which could potentially impact Evogene's future revenue streams and market position.Evogene reported its fourth quarter and full year 2024 financial results, which showed a latest annual turnover of USD 8.51M and an annual profit of USD -16.49M. The company's financial performance is a key factor that investors consider when evaluating the stock's potential.
Ainvest Movers Radar
Knowing stock market today at a glance
Latest Articles
RTX Stock Rallies 4.83% on $1.7B Patriot Contract Win, Geopolitical Tensions Drive Defense Demand
Dec.23 2025
Lam Research Drops 0.27% to Monthly Low Amid Catalyst Vacuum
Dec.23 2025
PowerBank (SUUN) Surges 36.17% on Strategic $41M Solar Deal PowerBank (SUUN) Surges 36.17% on Strategic $41M Solar Deal
Dec.23 2025
Carnival Corporation Shares Plunge 2.73% as Macroeconomic Headwinds Offset Record 2025 Earnings
Dec.23 2025
Nasdaq Composite Hits Monthly High with 0.84% Surge, Extends 6-Day Rally to 5.47% on Trump-Fed Rhetoric
Dec.23 2025
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet